ASCO 2014

asco xAmerican Society of Clinical Oncology (ASCO)
2014 Annual Meeting

May 30 - June 3, 2014

McCormick Place
Chicago, IL USA

#ASCO14 - Poster: Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence

CHICAGO, IL USA (UroToday.com) - Presented by Bajorin DF,1 Gomella LG,2 Sharma P,3 Plimack ER,4 O’Donnell PH,5 Hoffman-Censits J,2 Flaig TW,6 Quinn DI,7 Campogan D,8 Haynes H,8 McCoy C,8 Maher J,8 DeVries T,8 Sheikh N,8 and Lerner SP9 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

#ASCO14 - Poster: Activity of abiraterone acetate in metastatic castration-resistant prostate cancer patients previously treated with ketoconazole: A prospective phase II study from the Prostate Cancer Clinical Trials Consortium

CHICAGO, IL USA (UroToday.com) - Presented by Won Kim, John Wilton, Li Zhang, Amy M. Lin, Lawrence Fong, Andrew Caleb Hsieh, Terence W. Friedlander, Rahul Raj Aggarwal, Vivian K. Weinberg, Allison Morse, Jeffrey Bozeman, Arturo Molina, Gerald J. Fetterly, James Mohler, Russell Zelig Szmulewitz, Eric Jay Small, and Charles J. Ryan at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

#ASCO14 - The site of visceral metastases to predict overall survival in castration-resistant prostate cancer (CRPC) patients: A meta-analysis of five phase III trials - Session Highlights

CHICAGO, IL USA (UroToday.com) - Several previous studies, as well as clinical practice, suggest that the site of metastatic disease influences overall survival among men with metastatic castrate resistant prostate cancer (CRPC).

#ASCO14 - Final results of EORTC intergroup randomized phase III trial comparing immediate vs deferred chemotherapy after radical cystectomy in patients with pT3T4 and/or N+ M0 transitional cell carcinoma (TCC) of the bladder - Session Highlights

CHICAGO, IL USA (UroToday.com) - This study is an update on an EORTC intergroup phase III randomized controlled clinical trial of the effectiveness of immediate adjuvant chemotherapy, when used in patients with muscle-invasive bladder cancer, treated with radical cystectomy.

#ASCO14 - Association of higher institutional volume with improved overall survival in clinical stage III testicular cancer: Results from the National Cancer Data Base (1998-2011) - Session Highlights

CHICAGO, IL USA (UroToday.com) - Advances in treatment have improved survival outcomes among men with metastatic testicular germ cell tumors (TGCTs).

#ASCO14 - Poster: Establishing a neo-adjuvant platform for developing targeted agents: Androgen deprivation therapy prior to prostatectomy for patients with intermediate- and high-risk prostate cancer

CHICAGO, IL USA (UroToday.com) - Presented by K. A. Touijer, Y. Chen, B. S. Carver, J. A. Coleman, V. P. Laudone, M. Hullings, S. S. Ehrlich, M. DeNunzio, V. E. Reuter, J. A. Eastham, D. C. Danila, S. F. Slovin, M. J. Morris, Y. Chen, P. T. Scardino, H. I. Scher, and D. E. Rathkopf at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

#ASCO14 - Poster: PROSTVAC, PSA-targeted immunotherapy: New evidence for mechanism of action

CHICAGO, IL USA (UroToday.com) - Presented by Stefanie J. Mandl, Ryan B. Rountree, Rachel E. Owen, Tracy dela Cruz, Olivia Hwang, Gayatri Paranjpe, Amanda Enstrom, Alex Franzusoff, Carsten Goessl, and James B. Breitmeyer  at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

#ASCO14 - Poster: A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Preliminary clinical data

CHICAGO, IL USA (UroToday.com) - Presented by Emmanuel S. Antonarakis, Adam Stuart Kibel, George W. Adams, Lawrence Ivan Karsh, Aymen Elfiky, Neal D. Shore, Nicholas J. Vogelzang, John M. Corman, Robert Claude Tyler, Candice McCoy, Todd DeVries, Nadeem A. Sheikh, and Charles G. Drake at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

#ASCO14 - Poster: Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel

CHICAGO, IL USA (UroToday.com) - Presented by Anthony M. Joshua,1 Neal Shore,2 Fred Saad,3 Kim N. Chi,4 Carl A. Olsson,5 Urban Emmenegger,6 Mark Scholz,7 William Berry,8 Som D. Mukherjee,9 Eric Winquist,10 Naomi B. Haas,11 Nahla Hasabou,12 Carl Dmuchowski,12 Frank Perabo,12 Mohammad Hirmand,13 Margaret A. Foley,12 and Dana Rathkopf,14 for The Enzalutamide Expanded Access Study Investigators at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

#ASCO14 - Poster: Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo

CHICAGO, IL USA (UroToday.com) - Presented by Michael J. Morris,1 Yohann Loriot,2 Tomasz M. Beer,3 Celestia S. Higano,4 Andrew J. Armstrong,5 Cora N. Sternberg,6 Johann De Bono,7 Bertrand Tombal,8 Sarah B. Noonberg,9 Hank Mansbach,9 Suman Bhattacharya,9 Frank Perabo,10 De Phung,10 and Dana E. Rathkopf1 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

#ASCO14 - Poster: Enzalutamide monotherapy: 1-year extended follow-up of a Phase 2 study in hormone-naive prostate cancer patients

CHICAGO, IL USA (UroToday.com) - Presented by Bertrand Tombal,1 Michael Borre,2 Per Rathenborg,3 Patrick Werbrouck,4 Hendrick Van Poppel,5 Axel Heidenreich,6 Peter Iversen,7 Johan Braeckman,8 Jiri Heracek,9 Edwina Baskin-Bey,10 Taoufik Ouatas,10 Frank Perabo,11 De Phung,10 Mohammad Hirmand,12 Matthew R. Smith13 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

#ASCO14 - Poster: Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel

CHICAGO, IL USA (UroToday.com) - Presented by Karim Fizazi, Robert Jones, Stephane Oudard, Eleni Efstathiou, Fred Saad, Ronald De Wit, Johann Sebastian De Bono, Felipe Cruz, George Fountzilas, Albertas Ulys, Flavio Carcano, Neeraj Agarwal, David B. Agus, Joaquim Bellmunt, Daniel Peter Petrylak, Connie Lee, Bindu Tejura, Niels Geert Borgstein, and Robert Dreicer at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

#ASCO14 - Poster: Predicting response to abiraterone acetate: mRNA biomarker analysis of study COU-AA-302

CHICAGO, IL USA (UroToday.com) - Presented by Deborah Ricci,1 Weimin Li,2 Thomas W. Griffin,3 Michael Gormley,2 Erin Henitz,1 Charles J. Ryan,4 Johann S. de Bono,5 Gerhardt Attard,5 Alfons J.M. van den Eertwegh,6 Dirk Schrijvers,7 John Gullo,8 Henrik Suttmann,9 Joan Carles,10 Jose M. Piulats Rodriguez,11 Robert J. Jones,12 Christopher J. Logothetis,13 Dana E. Rathkopf,14 Howard I. Scher,14 and Eleni Efstathiou13 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

#ASCO14 - Poster: A randomized double-blind, comparative study of ARN-509 plus androgen deprivation therapy (ADT) vs ADT alone in non-metastatic castration-resistant prostate cancer–the SPARTAN trial

CHICAGO, IL USA (UroToday.com) - Presented by Matthew R. Smith,1 Glenn Liu,2 S. Martin Shreeve,3 Shannon Matheny,3 Antonieta Sosa,3 Thian Kheoh,3 Margaret K. Yu,3 and Eric J. Small4 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

#ASCO14 - Poster: Final analysis of a large, open-label global early access protocol with abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy

CHICAGO, IL USA (UroToday.com) - Presented by Cora N. Sternberg,1 Gedske Daugaard,2 Lajos Géczi,3 Sebastien J. Hotte,4 Paul N. Mainwaring,5 Fred Saad,6 Ciro Souza,7 Miah H. Tay,8 José M. Tello Garrido,9 Luca Galli,10 Anil Londhe,11 Peter De Porre,12 Dan Atlan,13 Betty Goon,11 Emma Lee,12 Tracy McGowan,11 Vahid Naini,14 Mary B. Todd,15 Arturo Molina,16 and Daniel J. George17 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

#ASCO14 - Poster: Symptomatic skeletal events in patients with advanced prostate cancer: Results from a phase 3 trial of denosumab for the prevention of skeletal-related events

CHICAGO, IL USA (UroToday.com) - Presented by Laurence Klotz,1 Matthew Smith,2 Robert Coleman,3 Kenneth Pittman,4 Piotr Milecki,5 Rachel Wei,6 Arun Balakumaran,6 Karim Fizazi7 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

#ASCO14 - Poster: A randomized, open-label phase 2a study evaluating quantified bone scan response following treatment with radium-223 dichloride alone or in combination with abiraterone acetate or enzalutamide...

CHICAGO, IL USA (UroToday.com) - Full Title: #ASCO14 - Poster: A randomized, open-label phase 2a study evaluating quantified bone scan response following treatment with radium-223 dichloride alone or in combination with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer who have bone metastases

#ASCO14 - Poster: 15-year survival outcomes following primary androgen deprivation therapy for localized prostate cancer

CHICAGO, IL USA (UroToday.com) - Presented by Grace L. Lu-Yao, MPH, PhD,1 Peter C. Albertsen, MD,2 Dirk F. Moore, PhD,1 Weichung Shih, PhD,1 Yong Lin, ,PhD,1 Robert S. DiPaola, MD1,1 and Siu-Long Yao, MD1, 3 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

#ASCO14 - Poster: Time to chemotherapy following treatment with sipuleucel-T: Data from PROCEED

CHICAGO, IL USA (UroToday.com) - Presented by Pieczonka CM,1 Concepcion RS,2 Tutrone RF,3 Penson DF,4 Bailen JL,5 Olsson CA,6 Forrest JB,7 Kassabian V,8 Mehlhaff BA,9 Shore ND,11 Lance RS,11 Tyler RC,12 Sandler A,12 McCoy C,12 Whitmore JB,12 and Cooperberg MR13 at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

Page 1 of 2
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe